Generic Product News: March 2022

This month's generic product news features lanreotide injections, glycopyrrolate oral solution, and vasopressin.

Lanreotide Injection

Marketed by Cipla Limited

Compare To: Somatuline Depot

The FDA has approved Cipla’s lanreotide injection, which is indicated for the treatment of individuals with acromegaly and gastroenteropancreatic neuroendocrine tumors. The active ingredient, route of administration, and strengths are the same as Somatuline Depot from Ipsen Biopharmaceuticals Inc. The injection comes in 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL single-dose, prefilled syringes.

FOR MORE INFORMATION: cipla.com

Glycopyrrolate Oral Solution

Marketed by Par Pharmaceutical, Inc

Compare To: Cuvposa

Par has begun shipping glycopyrrolate, a 1 mg/5 mL oral solution, following final approval from the FDA. The drug is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurological conditions associated with abnormal drooling. This generic alternative is intended to help families afford the medication for their children, according to a company statement.

FOR MORE INFORMATION: endo.com

Doxycycline Hyclate Delayed-Release Tablets

Marketed by Alembic Pharmaceuticals

Compare To: Doryx Tablets

Alembic Pharmaceuticals has received final FDA approval for its doxycycline hyclate delayed-released tablets, which are now available in 75, 100, 150, and 200 mg. They are indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-released tablets and other antibacterial drugs. The tablets should be used only to prevent or treat infections that are proven or strongly suspected to be caused by susceptible bacteria.

FOR MORE INFORMATION: alembicpharmaceuticals.com

Vasopressin

Marketed by Eagle Pharmaceuticals, Inc

Compare To: Vasostrict

The FDA has approved vasopressin, which is indicated to increase blood pressure in adults with vasodilatory shock (eg, postcardiotomy or sepsis) who remain hypotensive despite catecholamines and fluids. The approval follows
the US District Court for the District of Delaware ruling that Eagle’s proposed vasopressin product does not infringe on any of the patents Par Pharmaceuticals Inc asserted against Eagle Pharmaceuticals. Adverse reactions to vasopressin may include bradycardia, decreased cardiac output, hyponatremia, tachyarrhythmias, and ischemia.

FOR MORE INFORMATION: parpharm.com